Montibus Capital Management’s Puma Biotechnology PBYI Stock Holding History

Montibus Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$2.32M	Buy	+43,269	New	+$2.33M	0.25%	90

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Montibus Capital Management's PBYI Position: Q3 2013 in Review

Montibus Capital Management opened a new position in Puma Biotechnology (PBYI) in Q3 2013: 43,269 shares worth $2.32M. The stake represents 0.25% of the portfolio and ranks #90 among its holdings.

92 funds tracked by Wall St. Rank hold PBYI as of Q3 2013.

Montibus Capital Management held 43,269 shares of Puma Biotechnology worth $2.32M as of Q3 2013.
Puma Biotechnology was a new Montibus Capital Management position in Q3 2013.
Puma Biotechnology made up 0.25% of Montibus Capital Management's portfolio in Q3 2013, its #90 holding.
92 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2013.

Based on Montibus Capital Management's 13F filing for Q3 2013, filed 13 Nov 2013.